Neuroprotective Mechanisms of Diabetes Medications in Alzheimer's Disease

Type 2 diabetes and Alzheimer's disease share key pathological features, including insulin resistance, chronic inflammation and vascular dysfunction. Antidiabetic agents such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors and sodium–glucose cotransporter 2 inhibitors have shown promise beyond glycaemic control by engaging multiple neuroprotective pathways. These agents restore impaired insulin signalling in the brain, enhance glucose uptake at the neurovascular interface and attenuate oxidative stress and mitochondrial dysfunction. They also modulate neuroinflammatory cascades by inhibiting microglial activation and astrocyte reactivity, leading to reduced release of proinflammatory cytokines. Some compounds promote autophagy and clearance of aggregated proteins, while others support synaptic plasticity and neurogenesis. Collectively, these mechanisms converge to preserve neuronal viability, slow synaptic loss and mitigate cognitive decline. The global significance of repurposing established diabetes drugs lies in their well-characterised safety profiles and potential to provide disease-modifying benefits in Alzheimer’s disease.

Research from Nature Portfolio

Recent clinical studies have demonstrated that six-month treatment with a GLP-1 analogue significantly increased blood–brain glucose transfer capacity in patients with Alzheimer’s disease. The intervention restored transporter function at the blood–brain barrier to levels observed in healthy controls, prevented decline in cerebral metabolic rate for glucose and was associated with maintained cognitive performance. These findings highlight the direct impact of incretin-based therapies on neurovascular metabolism in Alzheimer’s disease.

Neuroprotective Mechanisms of Diabetes Medications in Alzheimer's Disease publication trend

The graph below shows the total number of articles in neuroprotective mechanisms of diabetes medications in alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

GLP-1 receptor agonist: A compound that mimics the incretin hormone GLP-1, enhancing insulin secretion and exerting neuroprotective effects.

Blood–brain barrier: A selective endothelial interface that regulates the passage of molecules between the bloodstream and the brain.

Oxidative stress: Cellular damage caused by accumulation of reactive oxygen species exceeding antioxidant capacity.

Neuroinflammation: Activation of glial cells and release of inflammatory mediators within the central nervous system.

Synaptic plasticity: The ability of synapses to strengthen or weaken over time, essential for learning and memory.

References

1. Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment. Scientific Reports (2017).
2. Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists. Theranostics (2023).
3. Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease. Journal of Biomedical Science (2024).
4. Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease. Acta Neuropathologica Communications (2021).
5. Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model. PLOS ONE (2013).
6. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's disease. The Journal of Pathology (2018).